| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Bionano Genomics, Inc. (NASDAQ:BNGO) ("Bionano" or the "Company") today announced the pricing of a public offering of an aggregate of 5,000,000 shares of the Company's common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company's common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company's common stock (all the warrants, collectively, the "Series Warrants"), at a combined public offering price of $2.00 per share (or common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants will have an exercise price of $2.00 per share and will be immediately exercisable upon issuance. The Series E warrants will expire on the five-year anniversary of the date of issuance. The short-term Series F warrants will expire on the eighteen-month anniversary of the date of issuance. The closing of the offering is expected to occur on or about September 17, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering are expected to be approximately $10 million before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series Warrants, if fully exercised on a cash basis, will be approximately $20 million. No assurance can be given that any of the Series Warrants will be exercised. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.
Posted In: BNGO
